心不全POCおよびLOCデバイス市場：検査タイプ、デバイスタイプ、技術、エンドユーザー別-2025-2030年の世界予測

心不全POCおよびLOCデバイス市場は、2024年には2億6,711万米ドルとなり、2025年には3億192万米ドル、CAGR13.33%で成長し、2030年には5億6,618万米ドルに達すると予測されています。

急速に変化する今日のヘルスケア環境において、心不全POC（ポイント・オブ・ケア）およびLOC（ラボオンチップ）デバイスの領域は極めて重要な変革期を迎えています。技術革新と臨床需要の増加により、市場力学は急速に変化しています。本エグゼクティブサマリーでは、新たな動向、細分化された考察、競合ベンチマーキングを詳細に紹介し、利害関係者が市場成長の方向性を理解できるようにしています。洗練された診断手法と合理化された患者管理アプローチの統合は、従来のパラダイムを再構築しつつあります。革新的な検査プラットフォーム、洗練された機器アーキテクチャ、ユーザー重視の設計を導入することで、市場環境は緊急医療と診断精度のギャップを埋めています。

この分野での進化は、重要な技術的ブレークスルーと患者層の移り変わりの両方から影響を受けています。これらの機器の重要性は、心不全関連イベントの減少に不可欠なタイムリーで正確な診断を提供する能力にあります。迅速な意思決定が臨床の金字塔となる時代において、心不全POCおよびLOC機器は、卓越したエンジニアリングと医学的見識の融合の証しとなっています。高性能診断ツールの採用者が、より高い信頼性と使いやすさを提供するソリューションに軸足を移す中、業界全体の軌跡は、かつてないほどリアルタイムのデータが治療経路に情報を提供する未来を指し示しています。

本サマリーの目的は、市場のセグメンテーション、地域の影響力、戦略的洞察、実行可能な提言など、これらの進化するプラットフォームの可能性を活用しようとする意思決定者にとって不可欠な要素を概説することです。この要約では、現状を見直すだけでなく、心不全の早期診断と継続的管理を再定義する未来を予測する明確な物語を提供します。

さらに、規制の進化、患者の安全性の向上、デジタルエコシステムとの統合といった基礎的要因についても紹介しています。各要素は、市場に広く普及するための舞台設定において重要な役割を果たしています。実証的な証拠と包括的な市場調査に基づいて作成された本書は、経験豊富な専門家と業界初心者の双方に、成功への明確なロードマップを提供します。

心不全診断の情勢は大きく変わる

近年、心不全診断の状況は、革新的な技術とダイナミックな市場需要によって大きく変化しています。顕著な変化は、迅速で、分散化された、患者中心の診断ソリューションへの集団的な動きから生じています。テクノロジーの進化は、ワークフローを合理化するだけでなく、早期発見と継続的なモニタリングを促進するという従来の医療インフラの役割も再定義しています。リアルタイムのデータと即時の意思決定が重視されることで、心臓の異常をタイムリーに特定することで患者の転帰が大幅に改善されるという新たな物語が形成されています。

ヘルスケア・プロバイダーは現在、検査室レベルの分析をポイント・オブ・ケア環境にもたらす高度診断ツールの統合をますます進めています。このシフトは、正確さ、スピード、使いやすさに対する強い要求に支えられています。煩雑な検査室での手順から、コンパクトで効率的なLOC機器への移行は、ゲームチェンジャーとなっています。小型化されたプラットフォームや診断プロセスのデジタル化などの進歩により、心不全管理は臨床転帰だけでなくヘルスケア現場での業務効率も支える進化を遂げました。

さらに、急速な技術の進歩により、複数の検査手法を統合した診断プラットフォームが可能になりました。このような技術の融合は、包括的なバイオマーカー解析、リアルタイムのモニタリング、効率的なデータ管理を包含する、患者ケアへの全体的なアプローチへの道を開いています。業界のリーダーたちは現在、拡張性、相互運用性、臨床的堅牢性を備えたシステムの構築に注力しています。デジタルヘルスプラットフォームに最新のセンサー技術を注入することで、近い将来、疾病管理プロトコルに革命をもたらすと期待されるイノベーションに拍車がかかっています。

競合するソリューションは、従来の臨床環境以外でも診断にアクセスできるようにすることで、患者のエンパワーメントという哲学を中心に据えるようになってきています。このようなヘルスケアの民主化は、慢性疾患の継続的なケアを容易にする、携帯可能で使い勝手の良い機器へのシフトに根ざしています。ウェアラブル機器に生体データと実用的な知見を統合することは、市場のリーダーたちが取り組んでいる変革的アプローチの一例です。その結果、こうしたシフトはケアの提供方法を再構築するだけでなく、心不全診断の展望における市場の境界線と投資機会を再定義しています。

心不全POCおよびLOCデバイスに関する主要なセグメンテーション洞察

市場のセグメンテーションを包括的に理解することは、心不全POCおよびLOCデバイスの微妙な状況を読み解く上で極めて重要です。セグメンテーションは、特定の臨床ニーズに対応するために診断法を調整する上で極めて重要な役割を果たします。セグメンテーションの分析的アプローチにより、市場は検査タイプ、デバイスタイプ、テクノロジー、エンドユーザーに基づいて方法論的に分割されることが明らかになりました。それぞれのセグメンテーション基準は明確なカテゴリーを包含しており、それによって市場戦略や開発努力の指針となっています。

検査タイプでは、市場はゲノム検査、メタボローム検査、プロテオーム検査に区分されます。これらの検査タイプはそれぞれ、心不全の分子基盤を捉える上でユニークな視点を提供し、早期診断と効果的な管理戦略のための強固なプロファイルを臨床医に提供します。ゲノム検査では遺伝性危険因子の同定が可能であり、メタボローム検査では患者の健康を支える生化学的プロセスに関する洞察が得られます。一方、プロテオミクス検査は、タンパク質の動態と心機能との関係に関する正確な情報を提供します。

デバイスの種類を細分化すると、診断用デバイスとウェアラブルデバイスに分けられます。診断機器は、心臓バイオマーカー分析装置、心臓画像診断装置、心電図（ECG）システムで構成され、高精度の検査室機能をベッドサイドにもたらします。これらの機器は、正確なデータを迅速に提供するように設計されており、急性期環境における迅速な臨床判断を促進します。体外式除細動器や心拍数モニターを含むウェアラブル機器は、病院の枠にとらわれない継続的でリアルタイムの患者モニタリングへのシフトを象徴しています。非侵襲的診断におけるこれらの機器の役割は、管理された環境で行われるより精巧な評価を補完するものです。

技術面では、バイオセンサーベースのシステム、イメージングとインピーダンスベースのプラットフォーム、イムノアッセイ、核酸ベースのプラットフォームが注目されています。これらの技術革新は、効果的な心不全診断に不可欠な感度と特異性のレベルを保証するものです。これらの技術革新は、先端材料とマイクロ流体工学を活用し、迅速な信号処理を提供し、デジタルカルテとシームレスに統合してデータ解析を強化します。

最後に、エンドユーザー別のセグメンテーションでは、福祉施設や在宅ケア施設から病院・診療所、専門検査室まで、さまざまな臨床環境を取り上げています。この広範なスペクトラムは、さまざまなケア環境のさまざまな運用要件と技術的能力を満たすために、市場の製品がいかに多様化されているかを示しています。多様なエンドユーザー環境に適応するこれらの機器の柔軟性は、その関連性を高め、市場への浸透を促進します。

各セグメンテーション層は、これらの機器の技術的・機能的パラメータを定義するだけでなく、開発の優先順位を患者やヘルスケア専門家の一般的なニーズと整合させる。これらの重要なセグメンテーションに関する洞察を理解することで、心不全診断ソリューションのイノベーションと展開を促進するメカニズムが明確になります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で心不全の有病率と発症率が増加しており、タイムリーな診断と管理デバイスの必要性が高まっています。
    • 心臓バイオマーカー分析における費用対効果が高くアクセスしやすいLOCデバイスの必要性の高まり
  • 抑制要因
    • 心不全POCおよびLOCデバイスの製品リコールに関する懸念の高まり
  • 機会
    • POCおよびLOCデバイスにデジタルヘルスプラットフォームと遠隔医療ソリューションを統合し、遠隔患者モニタリングを可能にする
    • 心不全POCおよびLOCデバイスの開発に向けたテクノロジー企業とヘルスケア提供者間の協力の強化
  • 課題
    • 心不全POCおよびLOCデバイスの採用に関連する規制およびコンプライアンスの問題
• 市場セグメンテーション分析
  • デバイスタイプ：心不全症例の早期発見のための心臓バイオマーカー分析装置としてPOCおよびLOCデバイスを活用する
  • テクノロジー：重要な心臓バイオマーカーのリアルタイム測定のためのバイオセンサーベースのシステムへの関心が高まっている
  • 試験の種類：心不全における疾患進行のモニタリングと治療介入の影響評価のためのメタボローム検査の採用
  • エンドユーザー：在宅ケア施設におけるポータブルで使いやすいPOCおよびLOCデバイスの利用増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 心不全POCおよびLOCデバイス市場テストの種類別

• ゲノム検査
• メタボローム検査
• プロテオーム検査

第7章 心不全POCおよびLOCデバイス市場：デバイスタイプ別

• 診断装置
  • 心臓バイオマーカー分析装置
  • 心臓画像診断装置
  • 心電図（ECG）
• ウェアラブルデバイス
  • 体外式除細動器
  • 心拍数モニター

第8章 心不全POCおよびLOCデバイス市場：技術別

• バイオセンサーベースのシステム
• イメージングおよびインピーダンスベースのプラットフォーム
• 免疫測定
• 核酸ベースのプラットフォーム

第9章 心不全POCおよびLOCデバイス市場：エンドユーザー別

• 介護付き生活ヘルスケア
• 在宅介護施設
• 病院と診療所
• 研究室

第10章 南北アメリカの心不全POCおよびLOCデバイス市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の心不全POCおよびLOCデバイス市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの心不全POCおよびLOCデバイス市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• ACON Laboratories Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMerieux S.A.
• Boston Scientific Corporation
• Cipla Limited
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Fukuda Denshi Co., Ltd.
• Jant Pharmacal Corporation
• Johari Digital India Limited by Syrma SGS
• Koninklijke Philips N.V.
• LifeSign LLC
• LifeSync
• Luminex Corporation by DiaSorin S.p.A.
• Mitsubishi Chemical Group Corporation
• Nexus Dx, Inc
• Nihon Kohden Corporation
• Quidel Corporation
• Schiller AG
• Shenzhen EDAN Instrument Co., Ltd.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Siemens Healthineers AG
• Spectral Diagnostics Inc.
• Trinity Biotech PLC

LIST OF FIGURES

• FIGURE 1. HEART FAILURE POC & LOC DEVICES MARKET MULTI-CURRENCY
• FIGURE 2. HEART FAILURE POC & LOC DEVICES MARKET MULTI-LANGUAGE
• FIGURE 3. HEART FAILURE POC & LOC DEVICES MARKET RESEARCH PROCESS
• FIGURE 4. HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2030 (USD THOUSAND)
• FIGURE 6. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 7. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 8. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 10. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 12. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 14. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 16. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 18. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 20. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 24. HEART FAILURE POC & LOC DEVICES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. HEART FAILURE POC & LOC DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. HEART FAILURE POC & LOC DEVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2030 (USD THOUSAND)
• TABLE 4. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 6. HEART FAILURE POC & LOC DEVICES MARKET DYNAMICS
• TABLE 7. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 8. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 9. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 10. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 11. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 12. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 13. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 14. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 15. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 16. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 17. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 18. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 19. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 20. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 21. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 22. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 23. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 24. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 25. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 26. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 27. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 28. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 29. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 30. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 31. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 32. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 33. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 34. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 35. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 36. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 37. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 38. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 39. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 40. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 41. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 42. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 43. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 44. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 45. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 46. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 47. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 48. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 49. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 50. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 51. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 52. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 53. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 54. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 55. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 56. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 57. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 58. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 59. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 60. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 61. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 62. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 63. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 64. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 65. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 66. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 67. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 68. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
• TABLE 69. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 70. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 71. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 72. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 73. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 74. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 75. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 76. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 77. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 78. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 79. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 80. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 81. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 82. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 83. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 84. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 85. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 86. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 87. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 88. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 89. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 90. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 91. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 92. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 93. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 94. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 95. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 96. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 97. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 98. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 99. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 100. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 101. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 102. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 103. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 104. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 105. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 106. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 107. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 108. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 109. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 110. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 111. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 112. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 113. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 114. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 115. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 116. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 117. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 118. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 119. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 120. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 121. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 122. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 123. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 124. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 125. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 126. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 127. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 128. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 129. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 130. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 131. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 132. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 133. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 134. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 135. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 136. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 137. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 138. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 139. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 140. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 141. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 142. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 143. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 144. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 145. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 146. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 147. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 155. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 156. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 157. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 158. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 159. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 160. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 161. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 162. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 163. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 164. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 165. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 166. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 167. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 168. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 169. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 170. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 171. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 172. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 173. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 174. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 175. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 176. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 177. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 178. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 179. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 180. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 181. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 182. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 183. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 184. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 185. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 186. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 187. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 188. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 189. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 190. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 191. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 192. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 193. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 194. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 195. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 196. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 197. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 198. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 199. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 200. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 201. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 202. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 203. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 204. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 205. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 206. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 207. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 208. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 209. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 210. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 211. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 212. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 213. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 214. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 215. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 216. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 217. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 218. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 219. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 220. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 221. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 222. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 223. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 224. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 225. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 226. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 227. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 228. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 229. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 230. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 231. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 232. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 233. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 234. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 235. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 236. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 237. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 238. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 239. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 240. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 241. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 242. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 243. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 244. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 245. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 246. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 247. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 248. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 249. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 250. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 251. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 252. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 253. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 254. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 255. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 256. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 257. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 258. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 259. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 260. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 261. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 262. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 263. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 264. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 265. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 266. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 267. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 268. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 269. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 270. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 271. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 272. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 273. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 274. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 275. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 276. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
• TABLE 277. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 278. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
• TABLE 279. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 280. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 281. HEART FAILURE POC & LOC DEVICES MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 282. HEART FAILURE POC & LOC DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

The Heart Failure POC & LOC Devices Market was valued at USD 267.11 million in 2024 and is projected to grow to USD 301.92 million in 2025, with a CAGR of 13.33%, reaching USD 566.18 million by 2030.

In today's fast-changing healthcare environment, the realm of heart failure point-of-care (POC) and laboratory-on-a-chip (LOC) devices is experiencing a pivotal transformation. Market dynamics are shifting rapidly, driven by technological innovations and increasing clinical demand. This executive summary provides an in-depth exploration of emerging trends, segmented insights, and competitive benchmarks, enabling stakeholders to comprehend the direction of market growth. The integration of sophisticated diagnostic methodologies with streamlined patient management approaches is reshaping traditional paradigms. By deploying innovative testing platforms, sophisticated device architectures, and user-focused design, the market landscape bridges the gap between urgent care and diagnostic precision.

The evolution in this space has been influenced by both critical technological breakthroughs and shifting patient demographics. The significance of these devices lies in their capability to deliver timely and accurate diagnostics, which are essential for reducing heart failure-related events. In an era where rapid decision-making is clinical gold, heart failure POC and LOC devices stand as a testament to the convergence of engineering excellence and medical insight. As adopters of high-performance diagnostic tools pivot towards solutions that offer enhanced reliability and ease of use, the overall trajectory of the industry points to a future where real-time data informs treatment pathways like never before.

This summary aims to outline essential components-including market segmentation, regional influence, strategic insight, and actionable recommendations-for decision-makers looking to harness the potential of these evolving platforms. It provides an articulate narrative that not only reviews current conditions but also projects a future that promises to redefine early diagnosis and ongoing management for heart failure.

Furthermore, the discussion introduces underlying factors such as regulatory evolution, patient safety enhancements, and integration with digital ecosystems. Each element plays a crucial role in setting the stage for widespread market adoption. Building on empirical evidence and comprehensive market research, this narrative is designed to empower both seasoned experts and industry newcomers with a clear roadmap for success.

Transformative Shifts in the Landscape of Heart Failure Diagnostics

The landscape of heart failure diagnostics has undergone transformative changes in recent years, largely driven by innovative technology and dynamic market demand. A marked shift stems from a collective move towards rapid, decentralized, and patient-centric diagnostic solutions. The evolution in technology is not only streamlining workflows but also redefining the roles of traditional medical infrastructures in facilitating early detection and continuous monitoring. The emphasis on real-time data and immediate decision-making has shaped a new narrative where patient outcomes are significantly improved through timely identification of cardiac anomalies.

Healthcare providers are now increasingly integrating advanced diagnostic tools that bring laboratory-level analysis to point-of-care settings. This shift is supported by a strong demand for accuracy, speed, and ease of use. The transition from cumbersome laboratory procedures to compact and efficient LOC devices has been a game-changer. With advancements such as miniaturized platforms and the digitization of diagnostic processes, heart failure management has experienced an evolution that supports not only clinical outcomes but also operational efficiency in healthcare settings.

Furthermore, rapid technological advancements have made it possible to combine multiple testing methodologies into unified diagnostic platforms. This convergence of technologies is paving the way for a holistic approach to patient care, one that encompasses comprehensive biomarker analysis, real-time monitoring, and efficient data management. Industry leaders are now focused on building systems that are scalable, interoperable, and clinically robust. The infusion of digital health platforms with the latest in sensor technology has spurred innovations that are expected to revolutionize disease management protocols in the near future.

Competing solutions are increasingly centered around the philosophy of patient empowerment, making diagnostics accessible outside traditional clinical settings. This democratization of healthcare is anchored in the shift towards portable and user-friendly devices that facilitate continuous care for chronic conditions. The integration of biometric data and actionable insights into wearable devices exemplifies the transformative approach undertaken by market leaders. Consequently, these shifts are not only reshaping how care is delivered but also redefining market boundaries and investment opportunities in the heart failure diagnostic landscape.

Key Segmentation Insights into Heart Failure POC & LOC Devices

A comprehensive understanding of market segmentation is crucial for decoding the nuanced landscape of heart failure POC and LOC devices. Segmentation plays a pivotal role in tailoring diagnostics to address specific clinical needs. An analytical approach to segmentation reveals that the market is methodically divided based on test type, device type, technology, and end user. Each segmentation criterion encapsulates distinct categories, thereby guiding market strategies and development efforts.

In terms of test type, the market is segmented across genomic testing, metabolomic testing, and proteomic testing. Each of these testing types offers a unique perspective on capturing the molecular underpinnings of heart failure, providing clinicians with a robust profile for early diagnosis and effective management strategies. Genomic testing allows for the identification of inherited risk factors, while metabolomic testing provides insight into the biochemical processes underpinning patient health. Proteomic testing, on the other hand, contributes precise information regarding protein dynamics and their relation to cardiac function.

Delving into device type, the segmentation distinguishes between diagnostic devices and wearable devices. Diagnostic devices, comprising cardiac biomarker analyzers, cardiac imaging devices, and electrocardiogram (ECG) systems, bring high-precision laboratory capabilities to the bedside. These instruments are engineered to deliver accurate data expeditiously, thereby facilitating rapid clinical decisions in acute settings. Wearable devices, including external defibrillators and heart rate monitors, represent a shift towards continuous and real-time patient monitoring outside hospital confines. Their role in non-invasive diagnostics complements the more elaborate assessments conducted in controlled environments.

When examining technology, the analysis highlights the prominence of biosensor-based systems, imaging and impedance-based platforms, immunoassays, and nucleic acid-based platforms. These technological innovations ensure a level of sensitivity and specificity that is vital for effective heart failure diagnosis. They leverage advanced materials and microfluidics, provide rapid signal processing, and integrate seamlessly with digital health records for enhanced data analytics.

Finally, the segmentation by end user addresses varied clinical environments ranging from assisted living healthcare and home care facilities to hospitals & clinics and specialized laboratories. This broad spectrum illustrates how market offerings are diversified to meet the varying operational requirements and technological capacities of different care settings. The flexibility of these devices to adapt to diverse end user environments amplifies their relevance and aids in widespread market penetration.

Each segmentation layer not only defines the technical and functional parameters of these devices but also aligns developmental priorities with prevailing patient and healthcare professional needs. Understanding these critical segmentation insights provides clarity on the mechanisms driving the innovation and deployment of heart failure diagnostic solutions.

Based on Test Type, market is studied across Genomic Testing, Metabolomic Testing, and Proteomic Testing.

Based on Device Type, market is studied across Diagnostic Devices and Wearable Devices. The Diagnostic Devices is further studied across Cardiac Biomarker Analyzers, Cardiac Imaging Devices, and Electrocardiogram (ECG). The Wearable Devices is further studied across External Defibrillator and Heart Rate Monitors.

Based on Technology, market is studied across Biosensor-based systems, Imaging & impedance-based platforms, Immunoassays, and Nucleic acid-based platforms.

Based on End User, market is studied across Assisted Living Healthcare, Home Care Facilities, Hospitals & Clinics, and Laboratory.

Key Regional Insights in the Global Heart Failure Device Market

The global market for heart failure POC and LOC devices exhibits distinct regional dynamics, reflecting a diverse landscape that is influenced by varying regulatory, economic, and demographic factors. Comprehensive regional insights are derived by evaluating market trends in the Americas, in Europe, Middle East & Africa, and in Asia-Pacific. Each region presents unique challenges and opportunities, driving both the adoption of advanced technologies and the evolution of patient care practices.

In the Americas, the market benefits from advanced healthcare infrastructure, robust R&D investments, and a high adoption rate of new technologies. This region is characterized by a strong tradition of innovation in medical devices, where consumer demands and healthcare excellence converge to propel the evolution of heart failure diagnostics. The convergence of policy support, investment in digital health, and shifting demographics make the Americas a key driver for global market expansion.

Europe, Middle East & Africa provides a varied landscape marked by a blend of established healthcare systems and emerging market dynamics. This region is notable for its rigorous regulatory standards and a diversified patient population that demands specialized diagnostics. Market players in this area are focusing on interoperability and integration of data analytics with traditional healthcare services, striving to maintain the balance between cutting-edge technology usage and cost-effectiveness. The region represents a fertile ground for innovations that support chronic disease management and patient monitoring, spearheading a move towards harmonized standards and collaborative healthcare initiatives.

Asia-Pacific stands out as a rapidly evolving market with significant growth potential driven by large patient populations and increasing healthcare investments. There is a strong momentum towards adopting advanced diagnostic tools, where local innovation meets global technological trends. With rising per capita incomes and escalating health awareness, the demand for POC and LOC devices in the heart failure domain is accelerating. This region is also witnessing remarkable collaborations between technological firms and healthcare institutions, further fueling industry growth through localized adaptation of global healthcare standards.

The regional analysis underscores the importance of targeted strategies that cater to the unique healthcare demands in different markets. The dynamic interplay of economic, regulatory, and ethnographic elements across these regions not only shapes the competitive landscape but also dictates the pace at which innovations are integrated into clinical practice. By comprehensively exploring these regional nuances, stakeholders gain the ability to navigate a multifaceted market environment, ensuring that diagnostic solutions are both effective and regionally tailored.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights in the Heart Failure Diagnostic Space

The competitive landscape of heart failure POC and LOC devices is marked by contributions from a range of established and emerging players whose collective efforts have significantly advanced diagnostic technology. Major companies are leveraging their deep industry experience, research capabilities, and innovative product pipelines to address the growing demand for rapid and reliable heart failure diagnostic platforms. Notable companies include Abbott Laboratories, ACON Laboratories Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux S.A., Boston Scientific Corporation, Cipla Limited, Danaher Corporation, F. Hoffmann-La Roche Ltd., Fukuda Denshi Co., Ltd., Jant Pharmacal Corporation, Johari Digital India Limited by Syrma SGS, Koninklijke Philips N.V., LifeSign LLC, LifeSync, Luminex Corporation by DiaSorin S.p.A., Mitsubishi Chemical Group Corporation, Nexus Dx, Inc, Nihon Kohden Corporation, Quidel Corporation, Schiller AG, Shenzhen EDAN Instrument Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Spectral Diagnostics Inc., and Trinity Biotech PLC. Each of these companies underscores different strategic priorities such as technological advancement, market expansion, and strategic partnerships.

Market frontrunners are pushing the envelope by focusing on integrating biosensor technology with miniaturized platforms capable of delivering laboratory-quality results at the point-of-care. Their R&D efforts are supplemented by strategic investments aimed at incorporating digital health and advanced data-processing capabilities into new devices. This approach not only improves diagnostic efficiency but also enhances patient outcome tracking, crucial for long-term disease management. These companies are continuously exploring avenues to reduce device turnaround times while maintaining clinical accuracy, positioning themselves as key drivers in the transformation of heart failure diagnostics.

In addition to technological innovations, many industry leaders are also concentrating on expanding their geographic footprint, ensuring that breakthrough diagnostic solutions reach more diverse patient populations. The robust product pipelines of these companies, combined with significant financial investments in next-generation diagnostic tools, are setting new industry standards. Their current initiatives include refining testing platforms to cater to specific clinical settings and maximizing output through device modularity and enhanced interoperability. Competitive dynamics are further enriched by strategic mergers, partnerships, and acquisitions, which are streamlining operations and reducing time-to-market for innovative diagnostics.

Overall, the market insights from leading companies reflect a concerted effort to overcome longstanding challenges in heart failure management. Their combined influence continues to elevate industry benchmarks, encouraging both incremental improvements and radical innovations. This interplay of competition and collaboration fosters an environment ripe for breakthrough developments, where technological superiority and responsive patient care coalesce into a new era for heart failure diagnostics.

The report delves into recent significant developments in the Heart Failure POC & LOC Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON Laboratories Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux S.A., Boston Scientific Corporation, Cipla Limited, Danaher Corporation, F. Hoffmann-La Roche Ltd., Fukuda Denshi Co., Ltd., Jant Pharmacal Corporation, Johari Digital India Limited by Syrma SGS, Koninklijke Philips N.V., LifeSign LLC, LifeSync, Luminex Corporation by DiaSorin S.p.A., Mitsubishi Chemical Group Corporation, Nexus Dx, Inc, Nihon Kohden Corporation, Quidel Corporation, Schiller AG, Shenzhen EDAN Instrument Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Spectral Diagnostics Inc., and Trinity Biotech PLC. Actionable Recommendations for Industry Leaders in Heart Failure Diagnostics

For industry leaders seeking to navigate the competitive arena of heart failure POC and LOC devices, several strategic recommendations emerge from a deep analysis of market dynamics, technological advancements, and evolving patient needs. To remain at the forefront of this rapidly changing landscape, companies should focus on establishing a robust innovation pipeline, embracing cross-disciplinary research, and leveraging data-driven insights to direct product development.

A key recommendation is to increase investments in R&D, with a focus on the integration of biosensor technology and advanced computational platforms. By fostering innovation in this space, companies can anticipate the next generation of diagnostic tools that merge rapid analysis with user-friendly interfaces. Scaling the pace of innovation is critical to meeting the dynamic demands of a market that is increasingly inclined towards personalized and decentralized care. In addition, collaboration with academic institutions and technology startups can infuse fresh perspectives that stimulate disruptive innovation in diagnostic methodologies.

Furthermore, it is essential to adopt a patient-centric approach in developing diagnostic instruments. Industry leaders must prioritize features such as portability, ease of use, and real-time data integration to enhance user engagement across varied clinical and non-clinical settings. Strategic partnerships with digital health platforms and telemedicine providers can also extend the reach of these diagnostic devices, thereby encompassing a broader user base. By aligning product development with holistic patient care strategies, companies can solidify their market position and drive favorable patient outcomes.

A strategic focus on emerging markets and regional diversity is another recommended pathway. By tailoring diagnostic solutions to meet specific regional needs-whether in the Americas, Europe, Middle East & Africa, or Asia-Pacific-companies can leverage local opportunities and comply with region-specific regulatory requirements. This regional customization not only bolsters market penetration but also builds brand credibility among diverse healthcare providers.

Lastly, proactive engagement in shaping regulatory policies is advised. As advancements in diagnostic technologies continue to outpace conventional regulatory frameworks, early dialogue with policy makers can help secure necessary certifications and streamline market entry. By maintaining open lines of communication with regulatory authorities, industry leaders can preemptively address potential compliance challenges, thereby ensuring a smoother innovation-to-market transition.

These actionable recommendations, when executed strategically, empower companies to navigate uncertainties, harness emerging opportunities, and ultimately set a new standard for excellence in heart failure diagnostic care.

Conclusion: The Future of Heart Failure POC & LOC Diagnostics

In conclusion, the heart failure diagnostic market is undergoing significant yet promising transformation, driven by an amalgamation of rapid technological advancements, innovative segmentation strategies, and aggressive market expansion. The convergence of molecular testing approaches, device diversification, and cross-functional technologies has culminated in the creation of devices that bridge the gap between speedy diagnostics and comprehensive patient care.

The insights provided throughout this analysis reinforce the potential of POC and LOC devices to dramatically reshape clinical pathways for heart failure management. Continuous innovation, meticulous market segmentation, and tailored regional strategies serve as cornerstones for advancing diagnostic precision while ensuring improved patient outcomes. Moreover, the competitive landscape is enriched by leading companies that are fervently investing in next-generation diagnostics, underscoring the dynamic nature of this industry.

This narrative has established a clear link between advanced diagnostic methodologies and the future trajectory of heart failure management. The strategic integration of genomic, metabolomic, and proteomic tests, combined with both advanced diagnostic and wearable device technologies, heralds a new era in personalized medicine. As market players continue to invest in R&D and foster strategic alliances, the future of heart failure diagnostics looks increasingly robust and patient-centric.

The insights drawn from advanced technology and innovative data integration promise to not only reduce diagnostic delays but also empower clinicians with actionable, real-time information. This evolution is poised to transform clinical decision-making processes and ensure that diagnostic tools are in lockstep with the evolving complexities of cardiac care. Ultimately, the success of these initiatives will depend on sustained innovation, thorough market understanding, and the ability to adapt to regional and global healthcare trends.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence and incidence of heart failure globally enhancing need for timely diagnosis and management device
    • 5.1.1.2. Rising need for cost-effective and accessible LOC device in cardiac biomarker analyse
  • 5.1.2. Restraints
    • 5.1.2.1. Rising concern associated with product recall of heart failure POC & LOC devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of digital health platforms and telemedicine solutions in POC & LOC devices to enable remote patient monitoring
    • 5.1.3.2. Increasing collaborations between technology firms and healthcare providers for development of heart failure POC & LOC devices
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory and compliance issue associated with adoptions of heart failure POC & LOC devices
• 5.2. Market Segmentation Analysis
  • 5.2.1. Device Type: Utilizating POC & LOC devices as cardiac biomarker analyzers for early detection in heart failure cases
  • 5.2.2. Technology: Rising preference for biosensor-based systems for real-time measurements of vital cardiac biomarkers
  • 5.2.3. Test Type: Adoption of metabolomic testing for monitoring disease progression and assessing impact of therapeutic interventions in heart failure
  • 5.2.4. End User: Increasing utilization of portable and user-friendly POC and LOC devices for home care facilities
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Heart Failure POC & LOC Devices Market, by Test Type

• 6.1. Introduction
• 6.2. Genomic Testing
• 6.3. Metabolomic Testing
• 6.4. Proteomic Testing

7. Heart Failure POC & LOC Devices Market, by Device Type

• 7.1. Introduction
• 7.2. Diagnostic Devices
  • 7.2.1. Cardiac Biomarker Analyzers
  • 7.2.2. Cardiac Imaging Devices
  • 7.2.3. Electrocardiogram (ECG)
• 7.3. Wearable Devices
  • 7.3.1. External Defibrillator
  • 7.3.2. Heart Rate Monitors

8. Heart Failure POC & LOC Devices Market, by Technology

• 8.1. Introduction
• 8.2. Biosensor-based systems
• 8.3. Imaging & impedance-based platforms
• 8.4. Immunoassays
• 8.5. Nucleic acid-based platforms

9. Heart Failure POC & LOC Devices Market, by End User

• 9.1. Introduction
• 9.2. Assisted Living Healthcare
• 9.3. Home Care Facilities
• 9.4. Hospitals & Clinics
• 9.5. Laboratory

10. Americas Heart Failure POC & LOC Devices Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Heart Failure POC & LOC Devices Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Heart Failure POC & LOC Devices Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Asda and PocDoc partner to expand access to heart health diagnostics
  • 13.3.2. AliveCor launches innovative point-of-care ECG tech in Europe
  • 13.3.3. Roche Diagnostics India launches NT-proBNP test for early detection of heart failure
  • 13.3.4. Polymedco secures FDA clearance for rapid PATHFAST hs-cTnI-II troponin test
  • 13.3.5. ACON Laboratories expands POC testing with On Call MultiPro launch
  • 13.3.6. Jana Care and Roche collaborate to develop at-home blood testing
  • 13.3.7. Cipla unveils Cippoint, a rapid point-of-care diagnostic device
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. F. Hoffmann-La Roche Ltd
  • 13.4.2. Siemens Healthineers AG
  • 13.4.3. Koninklijke Philips N.V.
  • 13.4.4. Danaher Corporation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ACON Laboratories Inc.
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. bioMerieux S.A.
• 6. Boston Scientific Corporation
• 7. Cipla Limited
• 8. Danaher Corporation
• 9. F. Hoffmann-La Roche Ltd.
• 10. Fukuda Denshi Co., Ltd.
• 11. Jant Pharmacal Corporation
• 12. Johari Digital India Limited by Syrma SGS
• 13. Koninklijke Philips N.V.
• 14. LifeSign LLC
• 15. LifeSync
• 16. Luminex Corporation by DiaSorin S.p.A.
• 17. Mitsubishi Chemical Group Corporation
• 18. Nexus Dx, Inc
• 19. Nihon Kohden Corporation
• 20. Quidel Corporation
• 21. Schiller AG
• 22. Shenzhen EDAN Instrument Co., Ltd.
• 23. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 24. Siemens Healthineers AG
• 25. Spectral Diagnostics Inc.
• 26. Trinity Biotech PLC